 |
| |
| Jan-24-19 | Initiated |
Maxim Group |
Buy |
$3 |
|
| Apr-17-17 | Initiated |
Ladenburg Thalmann |
Buy |
$4.50 |
|
| Jan-20-17 | Initiated |
H.C. Wainwright |
Buy |
$5 |
|
| Mar-22-16 | Reiterated |
Leerink Partners |
Outperform |
$11 → $9 |
|
| Jul-27-15 | Reiterated |
FBR Capital |
Outperform |
$23 → $11 |
|
| Mar-16-15 | Initiated |
FBR Capital |
Outperform |
$23 |
|
|
|
| Jan-28-19 08:30AM | Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients GlobeNewswire |
| Jan-25-19 04:05PM | Bellerophon Announces Closing of $7 Million Public Offering of Common Stock GlobeNewswire |
| Jan-23-19 06:00AM | Bellerophon Announces Pricing of $7 Million Public Offering of Common Stock GlobeNewswire -23.91% |
| Jan-22-19 04:44PM | Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire -7.57% |
| Jan-07-19 08:30AM | Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire +26.74% |
| Nov-21-18 08:55AM | Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire |
| Nov-16-18 01:32AM | DBV Technologies Appoints Daniel Tassé as Chief Executive Officer GlobeNewswire |
| Nov-07-18 09:36AM | Bellerophon Therapeutics: 3Q Earnings Snapshot Associated Press +8.33% |
| 08:30AM | Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire |
| Oct-09-18 08:30AM | Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire |
| Sep-10-18 11:40AM | 3 Biotech & Marijuana Stocks to Pay Attention to this Quarter ACCESSWIRE +28.18% |
| Aug-29-18 08:00AM | Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference GlobeNewswire |
| Aug-20-18 08:00AM | Todays Research Reports on Stocks to Watch:Tesla and Bellerophon Therapeutics ACCESSWIRE +10.75% |
| Aug-08-18 08:15AM | The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict Benzinga -15.34% |
| Aug-07-18 08:30AM | Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension GlobeNewswire -68.86% |
| Aug-01-18 09:16AM | Bellerophon Therapeutics: 2Q Earnings Snapshot Associated Press |
| 08:40AM | Bellerophon Provides Business Update and Reports Second Quarter 2018 Financial Results GlobeNewswire |
| Jun-15-18 09:13AM | 5 Biotech Stocks Under $10 Worthy of Investors' Attention Zacks |
| Jun-12-18 08:39AM | The Zacks Analyst Blog Highlights: Comtech Telecommunications, Echo Global Logistics, Shoe Carnival, Bellerophon Therapeutics and OFG Bancorp Zacks -6.00% |
| 08:00AM | Bellerophon Therapeutics to Participate on Panel at JMP Securities Life Sciences Conference GlobeNewswire |
| Jun-11-18 12:45PM | 5 Top-Ranked Small Caps to Buy as Trade Tensions Escalate InvestorPlace |
| 09:08AM | Bet on 5 Top-Ranked Small Caps as Trade Tensions Escalate Zacks |
| May-16-18 08:30AM | Bellerophon to Present Positive Results from Phase 2 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease at the American Thoracic Society 114th International Conference GlobeNewswire |
| May-10-18 08:45AM | Bellerophon Provides Business Update and Reports First Quarter 2018 Financial Results GlobeNewswire |
| May-08-18 08:30AM | Bellerophon Reaches Agreement with FDA on Study Design of Phase 2b Trial of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire |
| Apr-30-18 08:43AM | Exact Sciences (EXAS) in Focus: Stock Moves 11.6% Higher Zacks |
| Apr-19-18 09:35AM | 3 Biotech Stocks That Will Thrive Amid Market Instability InvestorPlace +5.31% |
| Apr-03-18 08:30AM | Bellerophon Therapeutics to Provide Corporate Update at H.C. Wainwright Annual Global Life Sciences Conference GlobeNewswire |
| Mar-27-18 07:00AM | Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018 ACCESSWIRE |
| Mar-23-18 10:56AM | Will Bellerophon Therapeutics (BLPH) Continue to Surge Higher? Zacks -8.39% |
| Mar-15-18 07:17PM | Bellerophon Therapeutics posts 4Q loss Associated Press |
| 04:45PM | Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire |
| Jan-29-18 08:30AM | Bellerophon Therapeutics Announces Enrollment Exceeds 100 Patients in Phase 3 INOvation-1 Study Evaluating INOpulse® for Treatment of Pulmonary Arterial Hypertension GlobeNewswire |
| Jan-03-18 08:30AM | Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease GlobeNewswire |
| Nov-30-17 05:46PM | Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors GlobeNewswire |
| Nov-07-17 08:43AM | Bellerophon Therapeutics posts 3Q loss Associated Press |
| 08:30AM | Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire |
| Sep-27-17 08:30AM | Bellerophon Announces $23 Million Private Placement GlobeNewswire +18.52% |
| Sep-07-17 04:01PM | Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences GlobeNewswire |
| Sep-05-17 08:40AM | Bellerophon shares surge 20% premarket on positive results in trial of COPD treatment MarketWatch |
| 08:30AM | Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease GlobeNewswire |
| Aug-07-17 11:57PM | Bellerophon Therapeutics posts 2Q loss Associated Press |
| 08:00AM | Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire |
| Aug-03-17 08:30AM | Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) GlobeNewswire |
| May-22-17 04:01PM | Positive Clinical Data on INOpulse® Presented at the American Thoracic Society 113th International Conference GlobeNewswire |
| May-16-17 08:00AM | Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics Accesswire |
| May-15-17 08:22AM | Bellerophon Therapeutics posts 1Q loss Associated Press -5.10% |
| 08:00AM | Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire |
| May-10-17 08:00AM | Bellerophon Announces $3.0 Million Registered Direct Offering GlobeNewswire |
| May-01-17 08:01AM | Bellerophon to Present Positive Clinical Data on INOpulse® at the American Thoracic Society 113th International Conference GlobeNewswire |
| Apr-07-17 11:05AM | Bellerophon Slumps on Underwhelming INOpulse Data Investopedia -10.20% |
| 07:00AM | Clinical Data on INOpulse® Presented at 37th Annual Meeting for the International Society for Heart and Lung Transplantation (ISHLT) GlobeNewswire |
| Mar-27-17 08:00AM | Bellerophon Announces Poster Presentation on INOpulse® at 37th Annual Meeting for the International Society for Heart and Lung Transplantation GlobeNewswire |
| Mar-21-17 09:30AM | The Difference Between Spectacular News and No News Accesswire |
| Mar-16-17 01:04PM | BELLEROPHON THERAPEUTICS, INC. Financials -5.13% |
| 06:15AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an |
| Mar-13-17 08:47AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement |
| 07:52AM | Bellerophon Therapeutics posts 4Q loss Associated Press |
| 07:30AM | Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update GlobeNewswire |
| 06:20AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report |
| Feb-23-17 08:10AM | LifeSci Capital Initiates Coverage of Bellerophon Therapeutics Accesswire -7.69% |
| Jan-20-17 07:15AM | Coverage initiated on Bellerophon Therapeutics by H.C. Wainwright |
| Jan-06-17 05:18PM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule |
| Jan-04-17 08:38AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits |
| 08:00AM | Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program GlobeNewswire |
| Dec-22-16 01:10PM | These 5 Stocks Under $10 Could Make You a Lot of Money TheStreet.com |
| 01:10PM | These 5 Stocks Under $10 Could Make You a Lot of Money |
| Dec-12-16 05:26PM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers |
| Nov-29-16 05:11PM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a |
| Nov-23-16 06:30AM | Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering GlobeNewswire |
| Nov-15-16 05:09PM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or |
| Nov-09-16 10:21AM | Bellerophon Therapeutics posts 3Q loss |
| Nov-08-16 07:08AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement |
| 07:03AM | Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update GlobeNewswire |
| 06:40AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report |
| Nov-01-16 02:09PM | INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Bellerophon Therapeutics, Inc. and Advises Investors with Losses to Contact the Firm Business Wire |
| 12:50PM | Robbins Arroyo LLP is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders Business Wire |
| 10:15AM | SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Bellerophon Therapeutics, Inc. (BLPH) PR Newswire |
| Oct-31-16 08:00AM | Second Law Firm Hits Bellerophon (BLPH) at Investopedia |
| Oct-28-16 12:19PM | INVESTOR ALERT: Investigation of Bellerophon Therapeutics, Inc. Announced by Law Offices of Howard G. Smith Business Wire |
| Oct-26-16 01:29PM | Law Firm Targets Bellerophon Therapeutics (BLPH) at Investopedia |
| 09:02AM | Johnson & Weaver, LLP Initiates Investigations of Bellerophon Therapeutics, Inc., KemPharm, Inc., Neos Therapeutics, Inc., CommVault Systems, Inc. and Resource Capital Corp. PR Newswire |
| Sep-20-16 06:54AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers |
| 06:33AM | Bellerophon Therapeutics Announces Planned Management Transition by Year-End 2016 GlobeNewswire |
| Sep-06-16 06:37AM | Bellerophon to Present at the 18th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire |
| Aug-09-16 07:02AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement |
| 06:41AM | Bellerophon Therapeutics posts 2Q loss |
| 06:33AM | Bellerophon Reports Second Quarter 2016 Financial Results and Provides Business Update GlobeNewswire |
| Jul-27-16 07:54AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits |
| Jul-25-16 12:05PM | Bellerophon Gets Approval To Start Second Stage Study In PH-COPD |
| 06:03AM | Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD GlobeNewswire |
| Jun-17-16 04:53PM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders |
| Jun-16-16 06:44AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits |
| 06:03AM | Bellerophon Therapeutics Announces Enrollment of the First Patient in the INOvation-1 Phase 3 Clinical Trial for Pulmonary Arterial Hypertension (PAH) GlobeNewswire |
| May-27-16 04:34PM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements a |
| May-13-16 07:49AM | 6 Stocks Under $10 Making Big Moves Higher at TheStreet |
| May-10-16 07:17AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement |
| 06:46AM | Bellerophon Therapeutics posts 1Q loss |
| 06:33AM | Bellerophon Reports First Quarter 2016 Financial Results and Provides Business Update GlobeNewswire |
| 06:15AM | BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report |
|
|
|
|
| Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Peacock Jonathan M | Director | Jan 25 | Buy | 0.70 | 714,286 | 500,000 | 1,855,920 | Jan 25 04:21 PM | | Wang Theodore T | Director | Jan 25 | Buy | 0.70 | 450,000 | 315,000 | 463,699 | Jan 25 04:22 PM | | Amin Naseem | Director | Jan 25 | Buy | 0.70 | 571,429 | 400,000 | 1,818,867 | Jan 25 04:12 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 17 | Buy | 1.18 | 60,000 | 70,944 | 7,386,163 | Sep 17 04:46 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 17 | Buy | 1.18 | 60,000 | 70,944 | 7,386,163 | Sep 17 04:42 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 14 | Buy | 1.23 | 75,000 | 92,250 | 7,326,163 | Sep 17 04:46 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 14 | Buy | 1.23 | 75,000 | 92,250 | 7,326,163 | Sep 17 04:42 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 13 | Buy | 1.19 | 75,000 | 89,160 | 7,251,163 | Sep 17 04:46 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 13 | Buy | 1.19 | 75,000 | 89,160 | 7,251,163 | Sep 17 04:42 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 12 | Buy | 1.15 | 75,000 | 85,913 | 7,176,163 | Sep 12 09:00 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 12 | Buy | 1.15 | 75,000 | 85,913 | 7,176,163 | Sep 12 09:00 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 11 | Buy | 1.14 | 200,000 | 228,840 | 7,101,163 | Sep 12 09:00 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 11 | Buy | 1.14 | 200,000 | 228,840 | 7,101,163 | Sep 12 09:00 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 10 | Buy | 1.22 | 200,000 | 243,640 | 6,901,163 | Sep 12 09:00 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 10 | Buy | 1.22 | 200,000 | 243,640 | 6,901,163 | Sep 12 09:00 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 07 | Buy | 0.90 | 60,000 | 53,742 | 6,701,163 | Sep 07 05:45 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 07 | Buy | 0.90 | 60,000 | 53,742 | 6,701,163 | Sep 07 05:42 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 06 | Buy | 0.84 | 50,000 | 42,095 | 6,641,163 | Sep 07 05:45 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 06 | Buy | 0.84 | 50,000 | 42,095 | 6,641,163 | Sep 07 05:42 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 05 | Buy | 0.85 | 50,000 | 42,325 | 6,591,163 | Sep 07 05:45 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Sep 05 | Buy | 0.85 | 50,000 | 42,325 | 6,591,163 | Sep 07 05:42 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Aug 16 | Buy | 0.65 | 66,393 | 43,109 | 6,541,163 | Aug 16 07:33 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Aug 16 | Buy | 0.65 | 66,393 | 43,109 | 6,541,163 | Aug 16 07:31 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Aug 15 | Buy | 0.65 | 272,000 | 175,902 | 6,474,770 | Aug 16 07:33 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Aug 15 | Buy | 0.65 | 272,000 | 175,902 | 6,474,770 | Aug 16 07:31 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Aug 14 | Buy | 0.65 | 190,977 | 123,868 | 6,202,770 | Aug 16 07:33 PM | | VENROCK ASSOCIATES IV L P | 10% Owner | Aug 14 | Buy | 0.65 | 190,977 | 123,868 | 6,202,770 | Aug 16 07:31 PM |
|
|
|
|
|
|
